Lower serum β-CrossLaps in male cardiac transplant recipients treated without prednisolone

Authors

  • Günter Höfle,

    Corresponding author
    1. Department of Internal Medicine and Vorarlberg Institute of Vascular Investigation and Treatment (VIVIT), Landeskrankenhaus Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria
    Search for more papers by this author
  • Hannes Holzmüller,

    1. Department of Internal Medicine and Vorarlberg Institute of Vascular Investigation and Treatment (VIVIT), Landeskrankenhaus Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria
    Search for more papers by this author
  • Ghazaleh Gouya,

    1. Department of Internal Medicine and Vorarlberg Institute of Vascular Investigation and Treatment (VIVIT), Landeskrankenhaus Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria
    Search for more papers by this author
  • Klaus Hergan,

    1. Department of Radiology, Landeskrankenhaus Feldkirch, Feldkirch, Austria
    Search for more papers by this author
  • Michael Hubmann,

    1. Central Medical Laboratory of Feldkirch, Feldkirch, Austria
    Search for more papers by this author
  • Peter Langer,

    1. Department of Internal Medicine and Vorarlberg Institute of Vascular Investigation and Treatment (VIVIT), Landeskrankenhaus Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria
    Search for more papers by this author
  • Heinz Drexel

    1. Department of Internal Medicine and Vorarlberg Institute of Vascular Investigation and Treatment (VIVIT), Landeskrankenhaus Feldkirch, Carinagasse 47, 6807 Feldkirch, Austria
    Search for more papers by this author

E-mail: guenter.hoefle@lkhf.at, Tel.: +43-5522-3039262, Fax: +43-5522-3037510

Abstract

Post-transplantation bone disease is a frequent problem after successful cardiac transplantation. We performed a cross-sectional analysis of male heart transplant recipients in the late post-transplantation period. Nine patients (group A) had received immunosuppressive therapy with cyclosporin A and mycophenolate mofetil (steroid-free treatment), and 12 patients (group B) remained on triple-drug therapy, which included glucocorticosteroids. Bone mineral density status was analyzed by osteodensitometry and by markers of bone turnover. Osteopenia was common in both groups (44.4% in group A and 50% in group B) as was osteoporosis (30% and 33.3% in groups A and B, respectively). β-CrossLaps were significantly lower in sera of cardiac transplant recipients on double immunosuppressive (i.e., glucocorticosteroid-free) regimen than in sera of patients on triple-drug therapy (428.3, 109.4 vs 661.7, 337.0 pg/ml, P<0.05). Lower serum β-CrossLaps levels in patients undergoing glucocorticosteroid-free treatment may indicate a lower risk of bone deterioration in the long term.

Ancillary